Abstract
The nitrosoureas have been in clinical usage in the treatment of primary and secondary brain tumors since 1969. Either as a tribute to the activity of these drugs or as an example of our ineptness in discovering other active drugs, the nitrosoureas, particularly BCNU, remain our most active agents.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
